Biphasic Reactions in Emergency Department Anaphylaxis Patients: A Prospective Cohort Study
Abstract
BACKGROUND
Biphasic reaction rates and potential associated risk factors are not well understood.
OBJECTIVE
To evaluate biphasic reaction rates and associated risk factors.
METHODS
We prospectively enrolled patients with anaphylaxis at 2 Midwestern academic emergency departments (EDs). We gathered data using patient and ED provider surveys and a structured health record review. Biphasic reaction rates and clinically significant biphasic reaction rates, defined as recurrent reactions that met anaphylaxis diagnostic criteria or were treated with epinephrine, were calculated. Characteristics associated with biphasic reactions were assessed with logistic regression and reported with odds ratios (ORs) and 95% CIs.
RESULTS
Of 430 ED anaphylaxis visits, 31 (7.2%) patients had biphasic reactions; 22 (5.1%) had clinically significant biphasic reactions. The median time from anaphylaxis onset to first epinephrine dose was longer for patients with biphasic (78 minutes) than uniphasic courses (45 minutes) (P=.005). A biphasic course was associated with an ED setting of first epinephrine dose (OR, 3.72 [95% CI, 1.36-10.14]) and a delay of more than 30 minutes from symptom onset to first epinephrine dose (OR, 3.39 [95% CI, 1.13-10.18]), and was inversely associated with arrival by ambulance (OR, 0.18 [95% CI, 0.05-0.61]). A clinically significant biphasic reaction was associated with an ED setting of first epinephrine dose (OR, 3.32 [95% CI, 1.08-10.25]) and inversely associated with…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.